225 related articles for article (PubMed ID: 38291075)
1. Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma.
Webster NJG; Kumar D; Wu P
Sci Rep; 2024 Jan; 14(1):2500. PubMed ID: 38291075
[TBL] [Abstract][Full Text] [Related]
2. Degradation of splicing factor SRSF3 contributes to progressive liver disease.
Kumar D; Das M; Sauceda C; Ellies LG; Kuo K; Parwal P; Kaur M; Jih L; Bandyopadhyay GK; Burton D; Loomba R; Osborn O; Webster NJ
J Clin Invest; 2019 Aug; 129(10):4477-4491. PubMed ID: 31393851
[TBL] [Abstract][Full Text] [Related]
3. PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.
Chen D; Zhao Z; Chen L; Li Q; Zou J; Liu S
Cell Death Dis; 2021 Jul; 12(8):722. PubMed ID: 34290239
[TBL] [Abstract][Full Text] [Related]
4. Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.
Wang H; Lekbaby B; Fares N; Augustin J; Attout T; Schnuriger A; Cassard AM; Panasyuk G; Perlemuter G; Bieche I; Vacher S; Selves J; Péron JM; Bancel B; Merle P; Kremsdorf D; Hall J; Chemin I; Soussan P
Hepatol Int; 2019 Jul; 13(4):454-467. PubMed ID: 31140152
[TBL] [Abstract][Full Text] [Related]
5. SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells.
Lee J; Seo G; Hur W; Yoon SK; Nam SW; Lee JH
Anticancer Res; 2020 Apr; 40(4):2033-2042. PubMed ID: 32234894
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma.
Kumar D; Das M; Oberg A; Sahoo D; Wu P; Sauceda C; Jih L; Ellies LG; Langiewicz MT; Sen S; Webster NJG
Adv Sci (Weinh); 2022 Jul; 9(21):e2105120. PubMed ID: 35615981
[TBL] [Abstract][Full Text] [Related]
7. Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice.
Sen S; Langiewicz M; Jumaa H; Webster NJ
Hepatology; 2015 Jan; 61(1):171-83. PubMed ID: 25132062
[TBL] [Abstract][Full Text] [Related]
8. Loss of Splicing Factor SRSF3 Impairs Lipophagy Through Ubiquitination and Degradation of Syntaxin17 in Hepatocytes.
Li Y; Wang T; Liao Q; Luo X; Wang X; Zeng S; You M; Chen Y; Ruan XZ
J Lipid Res; 2023 Mar; 64(3):100342. PubMed ID: 36764525
[TBL] [Abstract][Full Text] [Related]
9. Alternative splicing: a bridge connecting NAFLD and HCC.
Xu K; Wu T; Xia P; Chen X; Yuan Y
Trends Mol Med; 2023 Oct; 29(10):859-872. PubMed ID: 37487782
[TBL] [Abstract][Full Text] [Related]
10. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.
Li Y; Xu J; Lu Y; Bian H; Yang L; Wu H; Zhang X; Zhang B; Xiong M; Chang Y; Tang J; Yang F; Zhao L; Li J; Gao X; Xia M; Tan M; Li J
Cell Metab; 2021 Oct; 33(10):2004-2020.e9. PubMed ID: 34614409
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Knockdown of Splicing Regulator Slu7 Ameliorates Inflammation and Attenuates Liver Injury in Ethanol-Fed Mice.
Wang J; Kainrad N; Shen H; Zhou Z; Rote P; Zhang Y; Nagy LE; Wu J; You M
Am J Pathol; 2018 Aug; 188(8):1807-1819. PubMed ID: 29870742
[TBL] [Abstract][Full Text] [Related]
12. Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death.
Arif W; Mathur B; Saikali MF; Chembazhi UV; Toohill K; Song YJ; Hao Q; Karimi S; Blue SM; Yee BA; Van Nostrand EL; Bangru S; Guzman G; Yeo GW; Prasanth KV; Anakk S; Cummins CL; Kalsotra A
Nat Commun; 2023 Feb; 14(1):551. PubMed ID: 36759613
[TBL] [Abstract][Full Text] [Related]
13. SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development.
Luo C; Cheng Y; Liu Y; Chen L; Liu L; Wei N; Xie Z; Wu W; Feng Y
Cancer Res; 2017 Mar; 77(5):1168-1178. PubMed ID: 28082404
[TBL] [Abstract][Full Text] [Related]
14. Alternative RNA Splicing in Fatty Liver Disease.
Wu P; Zhang M; Webster NJG
Front Endocrinol (Lausanne); 2021; 12():613213. PubMed ID: 33716968
[TBL] [Abstract][Full Text] [Related]
15. SRSF3 and HNRNPH1 Regulate Radiation-Induced Alternative Splicing of Protein Arginine Methyltransferase 5 in Hepatocellular Carcinoma.
Wen C; Tian Z; Li L; Chen T; Chen H; Dai J; Liang Z; Ma S; Liu X
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499164
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic SRSF3 in health and diseases.
Jia R; Zheng ZM
Int J Biol Sci; 2023; 19(10):3057-3076. PubMed ID: 37416784
[TBL] [Abstract][Full Text] [Related]
18. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
19. Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins.
Jiménez M; Urtasun R; Elizalde M; Azkona M; Latasa MU; Uriarte I; Arechederra M; Alignani D; Bárcena-Varela M; Álvarez-Sola G; Colyn L; Santamaría E; Sangro B; Rodriguez-Ortigosa C; Fernández-Barrena MG; Ávila MA; Berasain C
Nucleic Acids Res; 2019 Apr; 47(7):3450-3466. PubMed ID: 30657957
[TBL] [Abstract][Full Text] [Related]
20. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
